NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
29 trialsNCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03172299 2025-03-24
PROTECT
Centre Hospitalier Universitaire de Nice
Phase 3 Completed
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03730558 2025-01-22
ZETA
Institut Sainte Catherine
Completed
NCT02384759 2024-07-10
FOLFA
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03530267 2024-02-23
ELDERLY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT01782443 2023-08-14
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03279289 2023-04-13
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT03043729 2023-02-06
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
AIO-Studien-gGmbH
Phase 2 Completed
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02340949 2021-05-03
RIA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT04810585 2021-03-23
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Yonsei University
Phase 4 Unknown
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04252456 2020-02-05
DISTINCTIVE
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase NA Unknown
NCT02331927 2019-09-20
PERMAD
University of Ulm
Phase 2 Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT02624726 2019-02-22
MINOAS
Hellenic Oncology Research Group
Phase 2 Unknown
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed
NCT02129257 2017-10-24
AMALTHEA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT03264274 2017-08-31
AUSCOR
Barts & The London NHS Trust
Phase 2 Withdrawn
NCT02079220 2017-07-31
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT01749956 2017-02-07
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT02235324 2015-05-06
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
University of Southern California
Phase 2 Withdrawn
NCT01941173 2014-07-21
Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
City of Hope Medical Center
Phase NA Withdrawn
NCT00601991 2013-04-02
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn